FRANKFURT (Reuters) -Swiss drugmaker Roche said on Thursday its first-quarter sales rose a forecast-beating 7% driven by ...

Roche posted higher-than-expected first-quarter sales, driven by robust demand for its key drugs, as the company takes active ...

Roche’s exposure to the tariffs is mostly limited to four medicines, three of which it already produces in the U.S., ...

The move will also create 12,000 new jobs across the United States, with 6,500 in construction and 1,000 at “new and expanded ...

Roche will invest $50 billion in U.S. manufacturing, including a new plant in Indiana. The Trump administration is ...

Roche said on Tuesday it would invest $50 billion in the United States over the next five years, creating more than 12,000 ...

Roche is working to mitigate potential impacts from tariffs by moving production of its medicines to the U.S. and petitioning ...

Roche posted a Q1 revenue beat, with strong contributions from Phesgo, Xolair, and Polivy, despite larger products lagging.

Xofluza (baloxavir marboxil) met its primary endpoint in the CENTERSTONE trial, reducing the odds of untreated household ...

April 22 (UPI) -- Biotechnology giant Roche said it will invest $50 billion into the United States over the next five years.

Seductive Reasoning,” a flop that preceded the Roches’ debut, has a fluctuating sonic palette, contributions from Paul Simon ...

The Basel-based company said the investment would go toward high-tech research and development sites and new manufacturing ...